Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme

Active Grant Awarded Last action

Award ID
R44CA275508
Recipient
Awarding agency
Obligated
$1,988,413

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 82% complete
Originally
Place of performance
Rochester, MN 55905, USA

Award details come from USAspending.gov.

Description

Abstract
Glioblastoma multiforme (GBM) is a rare and deadly cancer. First line treatment for GBM includes maximal surgical resection with radiotherapy administered post-surgery, and concomitant administration of adjuvant temozolomide. Tumor recurrence is nearly inevitable due to the microscopic, infiltrating cells that are found centimeters from the margin of visible tumor mass. There is currently no effective standard of care for recurrent (RGBM) and this highly aggressive disease leads to death within 15 months after diagnosis and has a 5-year survival rate of

Transactions

Action Obligated Date
Amendment $497,384
Amendment $796,215
Amendment $0
Amendment $0
Amendment $0
Original award $694,814

Quick answers

Who received award R44CA275508?

R44CA275508 was awarded to Sonalasense, Inc. by National Cancer Institute (National Institutes of Health) on March 21, 2023.

How much is award R44CA275508 worth?

$1,988,413 has been obligated on R44CA275508.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award